BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 19304556)

  • 1. Investigation of the structural requirement for inhibiting HIV integrase: QSAR study.
    Dessalew N
    Acta Pharm; 2009 Mar; 59(1):31-43. PubMed ID: 19304556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. QSAR study on dual 5-HT1A and 5-HT1B antagonists: an insight into the structural requirement for antidepressant activity.
    Dessalew N
    Arch Pharm (Weinheim); 2008 May; 341(5):314-22. PubMed ID: 18389517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and optimization of tricyclic phtalimide analogues as novel inhibitors of HIV-1 integrase.
    Verschueren WG; Dierynck I; Amssoms KI; Hu L; Boonants PM; Pille GM; Daeyaert FF; Hertogs K; Surleraux DL; Wigerinck PB
    J Med Chem; 2005 Mar; 48(6):1930-40. PubMed ID: 15771437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploring molecular shape analysis of styrylquinoline derivatives as HIV-1 integrase inhibitors.
    Leonard JT; Roy K
    Eur J Med Chem; 2008 Jan; 43(1):81-92. PubMed ID: 17452064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. QSAR study of substituted 1,3,4-oxadiazole naphthyridines as HIV-1 integrase inhibitors.
    Ravichandran V; Shalini S; Sundram K; Sokkalingam AD
    Eur J Med Chem; 2010 Jul; 45(7):2791-7. PubMed ID: 20347187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A platform for designing HIV integrase inhibitors. Part 1: 2-hydroxy-3-heteroaryl acrylic acid derivatives as novel HIV integrase inhibitor and modeling of hydrophilic and hydrophobic pharmacophores.
    Kawasuji T; Yoshinaga T; Sato A; Yodo M; Fujiwara T; Kiyama R
    Bioorg Med Chem; 2006 Dec; 14(24):8430-45. PubMed ID: 17010623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CoMFA and CoMSIA 3D-QSAR studies on quionolone caroxylic acid derivatives inhibitors of HIV-1 integrase.
    Lu P; Wei X; Zhang R
    Eur J Med Chem; 2010 Aug; 45(8):3413-9. PubMed ID: 20488589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Docking-based 3D-QSAR study of HIV-1 integrase inhibitors.
    Gupta P; Roy N; Garg P
    Eur J Med Chem; 2009 Nov; 44(11):4276-87. PubMed ID: 19647906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploring binding mode for styrylquinoline HIV-1 integrase inhibitors using comparative molecular field analysis and docking studies.
    Ma XH; Zhang XY; Tan JJ; Chen WZ; Wang CX
    Acta Pharmacol Sin; 2004 Jul; 25(7):950-8. PubMed ID: 15210071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery and structure-activity relationship studies of a unique class of HIV-1 integrase inhibitors.
    Dayam R; Sanchez T; Neamati N
    ChemMedChem; 2006 Feb; 1(2):238-44. PubMed ID: 16892356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. QSAR study of carboxylic acid derivatives as HIV-1 Integrase inhibitors.
    Cheng Z; Zhang Y; Fu W
    Eur J Med Chem; 2010 Sep; 45(9):3970-80. PubMed ID: 20561721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beta-diketo acid pharmacophore hypothesis. 1. Discovery of a novel class of HIV-1 integrase inhibitors.
    Dayam R; Sanchez T; Clement O; Shoemaker R; Sei S; Neamati N
    J Med Chem; 2005 Jan; 48(1):111-20. PubMed ID: 15634005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemistry and structure-activity relationship of HIV-1 integrase inhibitor integracide B and related natural products.
    Singh SB; Ondeyka JG; Schleif WA; Felock P; Hazuda DJ
    J Nat Prod; 2003 Oct; 66(10):1338-44. PubMed ID: 14575434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis, biological evaluation and molecular modeling studies of quinolonyl diketo acid derivatives: new structural insight into the HIV-1 integrase inhibition.
    Vandurm P; Guiguen A; Cauvin C; Georges B; Le Van K; Michaux C; Cardona C; Mbemba G; Mouscadet JF; Hevesi L; Van Lint C; Wouters J
    Eur J Med Chem; 2011 May; 46(5):1749-56. PubMed ID: 21385662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV type 1 integrase inhibitors: from basic research to clinical implications.
    Jegede O; Babu J; Di Santo R; McColl DJ; Weber J; QuiƱones-Mateu M
    AIDS Rev; 2008; 10(3):172-89. PubMed ID: 18820719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 4-Hydroxy-5-pyrrolinone-3-carboxamide HIV-1 integrase inhibitors.
    Pace P; Spieser SA; Summa V
    Bioorg Med Chem Lett; 2008 Jul; 18(14):3865-9. PubMed ID: 18595690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cluster analysis and three-dimensional QSAR studies of HIV-1 integrase inhibitors.
    Yuan H; Parrill A
    J Mol Graph Model; 2005 Jan; 23(4):317-28. PubMed ID: 15670952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A platform for designing HIV integrase inhibitors. Part 2: a two-metal binding model as a potential mechanism of HIV integrase inhibitors.
    Kawasuji T; Fuji M; Yoshinaga T; Sato A; Fujiwara T; Kiyama R
    Bioorg Med Chem; 2006 Dec; 14(24):8420-9. PubMed ID: 17005407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multivariate QSAR study of 4,5-dihydroxypyrimidine carboxamides as HIV-1 integrase inhibitors.
    de Melo EB; Ferreira MM
    Eur J Med Chem; 2009 Sep; 44(9):3577-83. PubMed ID: 19327872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. QSAR study of curcumine derivatives as HIV-1 integrase inhibitors.
    Gupta P; Sharma A; Garg P; Roy N
    Curr Comput Aided Drug Des; 2013 Mar; 9(1):141-50. PubMed ID: 23286784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.